"Grace McCullough, a medical student at Queen's University, was moved to act after seeing first-hand the devastating effect blood cancer can have on patients during her placements at hospitals. The 22-year-old from Banbridge in Co Down, donated her cells at King's College London after being recruited by Belfast Marrow, a branch of the Anthony Nolan student volunteer network."

"Allogeneic stem cell transplantation represents a new milestone in our efforts to provide the very best cancer care and treatment in Qatar. The procedure's success underlines our ongoing journey to combat cancers of the blood with the most advanced treatment modalities. Significant advances have been made throughout Qatar. We now take on the challenge of making further advances in developing our knowledge and expertise in cancer prevention and treatment to decrease the incidence of cancer in Qatar and increase survival rates, ultimately aiming to free our population from this often-devastating disease.'' 

"Patients suffering from bone-marrow failure could have better quality of life and longer survival rates following approval by the Health Ministry to extend a clinical trial of a new placenta-based cell therapy in Israeli hospitals.'' 

"It was so great to catch up with Chief Meteorologist Chris Bradley, who will be part of the Leukemia & Lymphoma Society's “Light the Night” walk. The event is critical to funding life-saving treatments. We also talked about his recovery after a stem cell transplant in September. Chris told us that after three stays at The James Cancer Hospital, it is good to be home."

"Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse."

"Researchers are testing a drug called Alvocidib that targets a protein called CDK-9 which allow cancer cells to ignore signals to die. Alvocidib lets the chemotherapy in to kill the cancer cells. The Alvocidib Phase II clinical trials in AML enrolled more than 400 patients. The trial demonstrates that there is significant activity when alvocidib is combined with a dosing treatment that includes the standard of care agents cytarabine and mitoxantrone (ACM)."

"Current drug-based approaches for healing bone marrow dysfunction involve flooding the body with growth factors, which is extremely expensive and causes unintended consequences because of lack of selectivity," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen Biopharma. "By utilizing a cell-based approach that both modulates the immune system and stimulates production of blood cells, we aim to offer alternatives to the current approaches to treating patients with aplastic anemia."

"A group of medical researchers have recently claimed that using stem cell transplantation to treat patients with a serious but a very rare form of chronic blood cancer Juvenile Myelomonocytic Leukemia (JMML) has shown improved results."

"UCLA stem cell researchers have shown that a novel stem cell gene therapy method could lead to a one-time, lasting treatment for sickle cell disease — the nation’s most common inherited blood disorder."

"By simulating apoptosis in a tube lined with a cell death-causing protein, the Cellect kit effectively kills the immune response-inducing cells while leaving the very desirable stem cells intact for the transplant. They call this process “aposorting.” About 80 percent of the control group in his lab experiments developed graft vs. host disease. Using stem cells collected with Cellect technology, the numbers went down to about zero. Similar results were seen in vitro on human cells.Cellect will be recruiting patients for Phase I clinical trials in about one year, pending approval from the US Food and Drug Administration."